 
          51
        
        
          17.
        
        
          Yuen MF, Yuan HJ, Hui CK, et al. A large population study of spontaneous
        
        
          HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection:
        
        
          implications for antiviral therapy. Gut 2003;52:416—9.
        
        
          18.
        
        
          Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg
        
        
          seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35:1522-
        
        
          27.
        
        
          19.
        
        
          Brunetto MR, Olivari F, Colombatto P, et al. Use of hepatitis B surface antigen
        
        
          serum levels help to distinguish active from inactive hepatitis B virus genotype
        
        
          D carriers. Gastroenterology 2010;139:483—90.
        
        
          20. Papatheodoridis GV, Manesis EK, Manolakopoulos S, et al. Is there a meaningful
        
        
          serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e
        
        
          antigen-negative chronic hepatitis B virus infection? Hepatology 2008;48:1451—
        
        
          9.
        
        
          21.
        
        
          Castéra L, Bernard PH, Le Bail B, et al. Transient elastography and biomarkers
        
        
          for liver fibrosis assessment and follow-up of inactive hepatitis B carriers.
        
        
          Aliment Pharmacol Ther 2011;33:455—65.
        
        
          22.
        
        
          Hadziyannis SJ, Papatheodoridis GV. Hepatitis Be antigen negative chronic
        
        
          hepatitis B – natural history and treatment. Semin Liver Dis 2006;26:130–41.
        
        
          23.
        
        
          Tsang PS, Trinh H, Garcia RT, Phan JT, Ha NB, Nguyen H, et al. Significant
        
        
          prevalence of histologic disease in patients with chronic hepatitis B and mildly
        
        
          elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol
        
        
          2008;6:569—74.
        
        
          24.
        
        
          Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigennegative chronic hepatitis
        
        
          B. Hepatology, 2001;34:617-624
        
        
          25.
        
        
          Hadziyannis SJ, Papatheodoridis GV, Vassilopoulos D. Treatment of HBeAg-
        
        
          negative chronic hepatitis B. Semin Liver Dis. 2003;23:81-88.
        
        
          26.
        
        
          Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of
        
        
          interferon-alpha treated and untreated patients with HBeAg-negative chronic
        
        
          hepatitis B. J Hepatol. 2001;34:306-313.
        
        
          27.
        
        
          Raimondo G, Allain JP, Brunetto MR, Buendia MA, Chen DS, Colombo M, et
        
        
          al. Statements from the Taormina expert meeting on occult hepatitis  B virus
        
        
          infection. J Hepatol 2008;49:652–57.
        
        
          28.
        
        
          Knoll A, Pietrzyk M, Loss M, Goetz WA, Jilg W. Solid-organ transplantation in
        
        
          HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV
        
        
          reactivation. Transplantation 2005;79:1631–33
        
        
          Kronik Hepatit B Enfeksiyonunun Dođal Seyri ve Özel Durumlar